Source:http://linkedlifedata.com/resource/pubmed/id/12371620
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2002-10-9
|
pubmed:abstractText |
Clinical trials have shown that the type I interferon (IFN)-alpha/beta have some beneficial effects on organ-specific autoimmune diseases, such as Behcet's diseases and multiple sclerosis, although the precise mechanisms remain largely unresolved. T helper cells 1 (Th1)-mediated autoimmune responses are involved in the initiation and/or progression of human uveitis, such as Behcet's disease. The animal model of experimental autoimmune uveoretinitis (EAU), characterized by a monophasic clinical course, has contributed to the understanding of the pathogenesis of human uveitis. Th1 producing IFN-gamma induce EAU development, while Th2 producing IL-4/IL-10 prevent the disease. However, depending on the cytokine milieu, the pro-inflammatory cytokine IFN-gamma may attenuate the autoimmune responses and anti-inflammatory cytokine IL-4 exacerbates it. Chemokines also play a crucial role in EAU development, which might be resolved by Th2-mediated immune responses. The administration of IFN-alpha/beta prevents EAU development, accompanied by a diminished production of IFN-gamma/IL-10. Interestingly, however, IFN-alpha/beta also have some beneficial effects on patients with Th2-like phenotype in addition to Th1-like phenotypes. Thus, the immuno-modulatory action of IFN-alpha/beta may be dependent on the context of cytokine combination and/or their concentrations.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0004-069X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
243-54
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12371620-Animals,
pubmed-meshheading:12371620-Autoimmune Diseases,
pubmed-meshheading:12371620-Clinical Trials as Topic,
pubmed-meshheading:12371620-Humans,
pubmed-meshheading:12371620-Immunotherapy,
pubmed-meshheading:12371620-Interferon Type I,
pubmed-meshheading:12371620-Retinitis,
pubmed-meshheading:12371620-Uveitis
|
pubmed:year |
2002
|
pubmed:articleTitle |
Type I interferons as immunoregulatory molecules; implications for therapy in experimental autoimmune uveoretinitis.
|
pubmed:affiliation |
Department of Immunology, Tokyo Medical University, Japan. mizu@tokyo-med.ac.jp
|
pubmed:publicationType |
Journal Article,
Review
|